Skip to main content

Table 1 Baseline characteristics of ESTHER participants with information on dementia diagnosis and biomarkers of neurodegenerative diseases

From: Subjective cognitive complaints and blood biomarkers of neurodegenerative diseases: a longitudinal cohort study

 

Baseline (2000–2002)

Subgroup with biomarker measurements

p-valueb

Study sample (n = 5926), N (%)

Casesa (n = 226), N (%)

Controlsa (n = 476), N (%)

Sex

 Female

3224 (54.4)

127 (56.2)

259 (54.4)

 

 Male

2702 (45.6)

99 (43.8)

217 (45.6)

0.6573

Education

 ≤ 9 years

4219 (71.2)

187 (82.7)

367(77.1)

 

 10–11 years

868 (14.6)

16 (7.1)

49 (10.3)

 

 ≥ 12 years

719 (12.1)

15 (6.6)

51 (10.7)

0.0810

APOE ε4 genotype

APOE ε4 + c

1466 (24.7)

91 (40.3)

123 (25.8)

 

APOE ε4 − d

4148 (70.0)

124 (54.9)

341 (71.6)

< 0.0001

Lifetime history of depression

 Yes

860 (14.5)

33 (14.6)

63 (13.2)

 

 No

5063 (85.4)

193 (85.4)

413 (86.8)

0.6225

Lifetime history of diabetes

 Yes

822 (13.9)

47 (20.8)

66 (13.9)

 

 No

4971 (83.9)

176 (77.9)

407 (86.5)

0.0174

Lifetime history of cardiovascular disease

 Yes

456 (7.7)

29 (12.8)

28 (5.9)

 

 No

5352 (90.3)

193 (85.4)

440 (92.4)

0.0016

Subjective cognitive complaints

 No

1688 (28.5)

36 (15.9)

115 (24.2)

 

 Occasional

3501 (59.1)

142 (62.8)

303 (63.7)

 

 Persistent

737 (12.4)

48 (21.2)

58 (12.2)

0.0014

 

Mean (SD)

Mean (SD)

Mean (SD)

 

Age

61.6 (6.5)

66.9 (5.1)

61.2 (6.5)

< 0.0001

GFAP

n.a

132.5 (79.7)

86.7 (46.8)

< 0.0001

NFL

n.a

22.0 (11.9)

15.7 (8.3)

< 0.0001

p-tau181

n.a

2.1 (1.2)

1.7 (1.2)

< 0.0001

  1. Percentages might not sum up to 100 because of rounding and missing values
  2. GFAP glial fibrillary acidic protein, NfL neurofilament light chain, p-tau181 phosphorylated tau181, SD standard deviation
  3. aCases and controls from the nested case–control study embedded within the ESTHER cohort
  4. bp-values derived from t-test tests for continuous and chi-square tests for categorical variables
  5. cAPOE ε4 + ; participants carrying the APOE ε4 allele (ε2ε4, ε3ε4, ε4ε4)
  6. dAPOE ε4 − ; participants not carrying the APOE ε4 allele (ε2ε2, ε3ε2, ε3ε3)